L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ

American Journal of Hypertension

Volumn 27, Issue 3, 2014, Pages 460-470

  Zambrano, Sonia ^a   Blanca, Antonio J ^a   Ruiz Armenta, María V ^a   Miguel Carrasco, José L ^a   Arévalo, Miguel ^b   Mate, Alfonso ^a   Vázquez, Carmen M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

blood pressure; fibrosis; hypertension; kidney; L carnitine; L NAME; PPAR

Indexed keywords

BLOOD PRESSURE; FIBROSIS; HYPERTENSION; KIDNEY; L-CARNITINE; L-NAME; PPAR.;

ANIMALS; CARNITINE; CELLS, CULTURED; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FIBROSIS; HYPERTENSION; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MALE; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; PPAR GAMMA; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84894232191     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpt268     Document Type: Article

References (39)

1. Campese VM, Bianchi S, Bigazzi R. Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? Curr Opin Nephrol Hypertens 2000; 9:143-147.
2. Polichnowski AJ, Lu L, Cowley AW, Jr. Renal injury in angiotensin IINAME-induced hypertensive rats is independent of elevated blood pressure. Am J Physiol Renal Physiol 2011; 300:F1008-F1016.
3. Ritz E. Hypertension and kidney disease. Clin Nephrol 2010; 74:S39-S43.
4. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and-independent Smad pathways: the role of Smad3. Hypertension 2009; 54:877-884.
5. Zhao W, Chen SS, Chen Y, Ahokas RA, Sun Y. Kidney fibrosis in hypertensive rats: role of oxidative stress. Am J Nephrol 2008; 28:548-554.
6. Peng ZZ, Hu GY, Shen H, Wang L, Ning WB, Xie YY, Wang NS, Li BX, Tang YT, Tao LJ. Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. Nephrology (Carlton) 2009; 14:565-572.
7. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009; 302:148-158.
8. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106:1675-1680.
9. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009; 89:47-58.
10. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, Vazquez CM. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens 2008; 21:1231-1237.
11. Gonzalez W, Fontaine V, Pueyo ME, Laquay N, Messika-Zeitoun D, Philippe M, Arnal JF, Jacob MP, Michel JB. Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proinflammatory signals. Hypertension 2000; 36:103-109.
12. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002; 40:866-871.
13. Sharma S, Barton J, Rafikov R, Aggarwal S, Kuo HC, Oishi PE, Datar SA, Fineman JR, Black SM. Chronic inhibition of PPAR-gamma signaling induces endothelial dysfunction in the juvenile lamb. Pulm Pharmacol Ther 2013; 26:271-280.
14. Chen Y, Luo Q, Xiong Z, Liang W, Chen L, Xiong Z. Telmisartan counteracts TGF-beta1 induced epithelial-to-mesenchymal transition via PPAR-gamma in human proximal tubule epithelial cells. Int J Clin Exp Pathol 2012; 5:522-529.
15. Martin H. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutat Res 2010; 690:57-63.
16. Kalaiselvi T, Panneerselvam C. Effect of l-carnitine on the status of lipid peroxidation and antioxidants in aging rats. J Nutr Biochem 1998; 9:575-581.
17. Dayanandan A, Kumar P, Panneerselvam C. Protective role of L-carnitine on liver and heart lipid peroxidation in atherosclerotic rats. J Nutr Biochem 2001; 12:254-257.
18. Sayed-Ahmed MM, Khattab MM, Gad MZ, Mostafa N. L-carnitine prevents the progression of atherosclerotic lesions in hypercholesterolaemic rabbits. Pharmacol Res 2001; 44:235-242.
19. Sener G, Paskaloglu K, Satiroglu H, Alican I, Kacmaz A, Sakarcan A. L-carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol 2004; 43:698-705.
20. Miguel-Carrasco JL, Monserrat MT, Mate A, Vazquez CM. Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur J Pharmacol 2010; 632:65-72.
21. Mate A, Miguel-Carrasco JL, Vazquez CM. The therapeutic prospects of using L-carnitine to manage hypertension-related organ damage. Drug Discov Today 2010; 15:484-492.
22. Radler U, Stangl H, Lechner S, Lienbacher G, Krepp R, Zeller E, Brachinger M, Eller-Berndl D, Fischer A, Anzur C, Schoerg G, Mascher D, Laschan C, Anderwald C, Lohninger A. A combination of (omega-3) polyunsaturated fatty acids, polyphenols and L-carnitine reduces the plasma lipid levels and increases the expression of genes involved in fatty acid oxidation in human peripheral blood mononuclear cells and HepG2 cells. Ann Nutr Metab 2011; 58:133-140.
23. Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco JL, Arevalo M, Vazquez MJ, Mate A, Vazquez CM. L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-gamma expression. Biochem Pharmacol 2013; 85:937-944.
24. Wen G, Ringseis R, Rauer C, Eder K. The mouse gene encoding the carnitine biosynthetic enzyme 4-N-trimethylaminobutyraldehyde dehydrogenase is regulated by peroxisome proliferator-activated receptor alpha. Biochim Biophys Acta 2012; 1819:357-365.
25. Chen HH, Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Lin SL, Tsai WL, Chen TW, Chen TH. Peroxisome proliferator-activated receptor alpha plays a crucial role in L-carnitine anti-apoptosis effect in renal tubular cells. Nephrol Dial Transplant 2009; 24:3042-3049.
26. Rodriguez-Lopez AM, Flores O, Arevalo MA, Lopez-Novoa JM. Glomerular cell proliferation and apoptosis in uninephrectomized spontaneously hypertensive rats. Kidney Int Suppl 1998; 68:S36-S40.
27. Serati AR, Motamedi MR, Emami S, Varedi P, Movahed MR. L-carnitine treatment in patients with mild diastolic heart failure is associated with improvement in diastolic function and symptoms. Cardiology 2010; 116:178-182.
28. Ono H, Saitoh M, Ono Y, Ishimitu T, Matsuoka H. Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats. J Hypertens 2004; 22:1389-1395.
29. Daniels A, van Bilsen M, Goldschmeding R, van der Vusse GJ, V, van Nieuwenhoven FA. Connective tissue growth factor and cardiac fibrosis. Acta Physiol (Oxf) 2009; 195:321-338.
30. Montezano AC, Burger D, Ceravolo GS, Yusuf H, Montero M, Touyz RM. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clin Sci (Lond) 2011; 120:131-141.
31. Miana M, de Las HN, Rodriguez C, Sanz-Rosa D, Martin-Fernandez B, Mezzano S, Lahera V, Martinez-Gonzalez J, Cachofeiro V. Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPARgamma). J Physiol Pharmacol 2011; 62:87-94.
32. Stasi MA, Scioli MG, Arcuri G, Mattera GG, Lombardo K, Marcellini M, Riccioni T, De FS, Pisano C, Spagnoli LG, Borsini F, Orlandi A. Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPHoxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol 2010; 30:426-435.
33. Pignatelli P, Lenti L, Sanguigni V, Frati G, Simeoni I, Gazzaniga PP, Pulcinelli FM, Violi F. Carnitine inhibits arachidonic acid turnover, platelet function, and oxidative stress. Am J Physiol Heart Circ Physiol 2003; 284:H41-H48.
34. O'Brien D, Chunduri P, Iyer A, Brown L. L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats. Basic Clin Pharmacol Toxicol 2010; 106:296-301.
35. Omori Y, Ohtani T, Sakata Y, Mano T, Takeda Y, Tamaki S, Tsukamoto Y, Kamimura D, Aizawa Y, Miwa T, Komuro I, Soga T, Yamamoto K. L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 2012; 30:1834-1844.
36. Gomez-Amores L, Mate A, Vazquez CM. L-carnitine transport in kidney of normotensive, Wistar-Kyoto rats: effect of chronic L-carnitine administration. Pharm Res 2003; 20:1133-1140.
37. Eder K, Ringseis R. The role of peroxisome proliferator-activated receptor alpha in transcriptional regulation of novel organic cation transporters. Eur J Pharmacol 2010; 628:1-5.
38. Chao G, Zheng C, Meng D, Su J, Xie X, Li W, Henein M. Tei index: the earliest detectable cardiac structural and functional abnormality detectable in Hb Bart's foetal edema. Int J Cardiol 2009; 134:e150-e154.
39. Garrelds IM, Elliott GR, Pruimboom WM, Zijlstra FJ, Bonta IL. Effects of carnitine and its congeners on eicosanoid discharge from rat cells: implications for release of TNFalpha. Mediators Inflamm 1993; 2:S57-S62.